Introduction
============

Exacerbations are a recognized feature of chronic obstructive pulmonary disease (COPD) and result in considerable morbidity and increased mortality.[@b1-copd-7-789]--[@b8-copd-7-789] They are also associated with a greater decline in lung function and can adversely affect health status.[@b9-copd-7-789]--[@b13-copd-7-789] For these reasons, exacerbations have become a major outcome measure in a number of clinical trials[@b14-copd-7-789]--[@b25-copd-7-789] and are the subject of numerous translational research studies.[@b26-copd-7-789]--[@b29-copd-7-789] Patients with alpha-1 antitrypsin (AAT) deficiency, a subgroup of COPD, often present in the third or fourth decade with symptoms of chronic bronchitis and exertional breathlessness.[@b30-copd-7-789]--[@b32-copd-7-789] AAT deficiency is associated with development of emphysema, first described in 1963, disproportionate to smoking history at an earlier age than usual COPD.[@b32-copd-7-789] Patients with lung disease have symptoms in common with usual COPD with a high prevalence of chronic bronchitis and emphysema. Lung function tests in these patients confirm obstruction with air trapping, although some may have normal gas transfer.[@b33-copd-7-789] However, the symptoms, features, and treatment of exacerbations in this group are similar to those of usual COPD.[@b34-copd-7-789]

Characterization of an exacerbation episode has been based on three major symptoms, ie, increased breathlessness, sputum volume, and sputum purulence, together with the variable contribution of minor symptoms as described by Anthonisen et al.[@b35-copd-7-789] These symptoms and their combinations are especially used in guidelines to direct antibiotic therapy. In addition, the treatment required has also been used to grade the severity of the episode.[@b36-copd-7-789]

Nearly 50% of all COPD exacerbations defined by symptoms do not lead to the patient increasing or changing therapy, and are referred to as "unreported" or "untreated" episodes. These may reflect the patients' perception of and actual improvement in their well-being,[@b37-copd-7-789] but nevertheless may contribute to a decline in lung function and poorer health status.[@b11-copd-7-789],[@b12-copd-7-789]

Exacerbations occur more frequently in subjects with more severe COPD,[@b38-copd-7-789] although a linear relationship is difficult to demonstrate and the reporting of episodes does increase with age and lower forced expiratory volume in one second (FEV~1~).[@b39-copd-7-789] Factors known to predict exacerbation frequency are the presence of chronic bronchitis symptoms and frequent exacerbations in the previous year.[@b40-copd-7-789] The frequency of exacerbation in AAT-deficient COPD has been shown to correlate with the decline in gas transfer,[@b9-copd-7-789] and exacerbations have been shown to be associated with greater inflammation.[@b41-copd-7-789] In this group, augmentation therapies have been shown to reduce the frequency and severity of exacerbation and lung function decline.[@b42-copd-7-789],[@b43-copd-7-789] A delay in treatment initiation has been shown to affect the overall length of the episode adversely,[@b44-copd-7-789] although factors influencing the delay other than those mentioned above are largely unknown. There are not enough research data showing the predictors of exacerbation nature, severity, and recovery.[@b27-copd-7-789]

Although there is a suggestion that exacerbation may be more severe in patients who have AAT deficiency, peak flow changes with therapy did not differ, suggesting that response to therapy is similar in both groups.[@b45-copd-7-789] Treatment of the lung manifestations of AAT deficiency does not differ from the standard treatment of COPD.[@b34-copd-7-789]

The current study was carried out primarily to examine daily diary cards in order to study exacerbation features and outcomes in depth. AAT-deficient COPD patients are a good cohort in which to study the features of exacerbations, because they experience more exacerbations associated with their decline in lung function.[@b9-copd-7-789] In a previous study, we were able to show for the first time a clear difference between reported or "treated" exacerbations and unreported or "untreated" exacerbations and to identify potential reasons.[@b37-copd-7-789] The aim of this paper is to address further factors that influence resolution of the exacerbation, length of an episode, and delay in starting treatment.

Materials and methods
=====================

Subjects
--------

The study design and methods have been previously described in detail.[@b37-copd-7-789] In brief, the patients had AAT deficiency of the PiZ type (confirmed by isoelectric focusing) and were attending the ADAPT (Antitrypsin Deficiency Assessment and Programme for Treatment) unit at the University Hospital Birmingham NHS Trust, Birmingham, UK. Patients were participating in an intravenous augmentation therapy trial called EXACTLE (Exacerbations and CT scans as Lung Endpoints; ClinicalTrials.gov identifier: NCT00263887) and recorded and scored their symptoms (breathlessness, sputum color, and volume) on daily diary cards. This patient group has been the subject of a previous publication investigating the characteristics of reported (treated) and unreported (untreated) exacerbations.[@b37-copd-7-789] All patients had confirmed airflow obstruction as demonstrated by post bronchodilator spirometry. All had experienced at least one exacerbation in the previous year. Patients were reviewed weekly and diary cards were checked for consistency. Any change in therapy was documented on the diary cards and in the clinical notes. At the end of the study, the cards were collected from the patients and analyzed for exacerbations over 2 years, as described previously.[@b37-copd-7-789] Ethical approval for this study was obtained from the local research and ethics committees, and all patients provided their written informed consent before enrolling in the study.

Physiology and computed tomography methods
------------------------------------------

Baseline full lung function was assessed after administration of nebulized bronchodilators (salbutamol 5 mg and ipratropium bromide 500 μg) in the stable state. All patients had a baseline computed tomography scan at full inspiration and emphysema was visualized and quantified as the 15th percentile lung density (PD15) derived from computed tomographic images, as described previously.[@b46-copd-7-789]--[@b48-copd-7-789]

Identification of exacerbations
-------------------------------

The onset of exacerbation was defined as the first day of an increase in one or more major symptoms, compared with baseline, for at least 2 consecutive days.[@b36-copd-7-789] The end of exacerbation was defined as the first day of a return to the patient's usual clinical state as recorded for at least 2 consecutive days, defining the total length of the episode.

[Figure 1](#f1-copd-7-789){ref-type="fig"} shows a diagrammatic representation of the exacerbation length and its components. Also indicated are the delay in treatment (time taken for treatment to be initiated after the onset of exacerbation) and resolution of symptoms to baseline, defining the end of the exacerbation after commencement of treatment.

Weighting of scores
-------------------

The scores for the symptoms of breathlessness and well-being were weighted and multiplied by a factor of five as described previously.[@b37-copd-7-789] Any increase in instance of cough was given a score of one, and changes in sputum volume and color were scored as indicated on the diary card (Bronkotest^®^, Middlesex, UK). The change in combined score for any day was used as a marker of severity.

Statistics
----------

Statistical analysis was performed using the Statistical Package for the Social Sciences version 12 for Windows^®^ (SPSS Inc, Cary, NC). Data are presented as the mean (±standard error) or median (interquartile range) depending on the distribution. Statistical comparisons were performed used the Student's *t*-test for parametric data and Mann-Whitney U tests for nonparametric data. The Chi-square test was used for discrete variables, and the relationship between exacerbation frequency, length, treatment delay, and outcome to lung function were analyzed using the Spearman correlation. When more than one factor was related to the outcome, multivariate analysis was carried out to determine the best independent predictor.

Results
=======

Baseline characteristics
------------------------

Diary cards were analyzed for the 23 patients who completed the study for the period of 2 years. [Table 1](#t1-copd-7-789){ref-type="table"} summarizes their baseline characteristics as the mean ± standard error in parentheses. Of the patients, 16 had chronic sputum production and the mean score for sputum color and volume in the stable state was 1.5 ± 0.3 and 0.9 ± 0.2, respectively. Twenty-one patients were receiving regular, long-acting inhaled bronchodilator therapy (long-acting β~2~ agonists/long-acting anticholinergics) and 18 patients were also on inhaled corticosteroids. The mean dose of inhaled corticosteroid was 1226.1 ± 211.6 μg per day of beclomethasone dipropionate or equivalent (median/interquartile range 1000 \[400--2000\]). No patients were receiving long-term systemic corticosteroids. During this trial, 11 of the subjects received active drug.

Frequency of exacerbations
--------------------------

A total of 263 episodes (164 treated and 99 untreated) were identified on the 23 diary cards over a period of 24 months. The median (interquartile range) total exacerbation rate was 5.0 (3.5--7.0) per patient per year, and consisted of 3.0 (2.5--4.5) treated episodes and 1.5 (0.5--3.0) episodes where the treatment remained unchanged. Untreated episodes were less likely to be associated with added symptoms suggestive of a coryzal illness, chest pain, or nocturnal symptoms (*P \<* 0.001). The treated episodes were characterized by more symptom scores, a longer duration of breathlessness, and worse well-being, with well-being central to patients seeking medical therapy. We discussed these results in detail in our previous published paper.[@b37-copd-7-789]

Treatment
---------

Of the 164 treated exacerbations, 31 were treated with increased inhaled bronchodilator therapy alone. Antibiotics were given for 130 exacerbations and, in the case of 50 episodes, patients received systemic steroids. There were 11 hospitalized episodes among five patients. Of the 164 episodes, complete daily diary card data (no missing days) were available for 81 episodes (for 17 of the patients enabling length to be determined) of which 61 were treated with antibiotics (12 episodes were also treated with steroids) and 51 episodes were purulent with a sputum color score of ≥3. Daily data were available for four episodes which required hospital admission.

### Factors affecting frequency of treated exacerbations

Of the 23 patients, one recorded no treated exacerbation and one had an excessive number (more than 10 in a year), which represented a clear outlier. For the remaining 21 patients, there was a significant negative correlation between corrected gas transfer (KCO% predicted) and frequency of treated episodes ([Table 2](#t2-copd-7-789){ref-type="table"} and [Figure 2](#f2-copd-7-789){ref-type="fig"}). No other baseline characteristic, including baseline PD15, was related to frequency of treated episodes.

### Factors affecting likelihood of an episode being treated

The likelihood of an episode being treated correlated negatively with FEV~1~% predicted and the FEV~1~/forced vital capacity (FVC) ratio ([Table 2](#t2-copd-7-789){ref-type="table"}). Other factors shown to affect the rate of treated episodes were the number of major symptoms outlined by Anthonisen et al,[@b35-copd-7-789] presence of cold-like symptoms, chest pain, and nocturnal symptoms as previously published[@b37-copd-7-789] (Chi-square, *P* \< 0.001 for all). Although all the above-mentioned factors significantly predicted the episodes that required treatment upon univariate analysis, when using the linear regression stepwise analysis, presence of cold-like symptoms was the best independent predictive factor (*P* \< 0.001).

### Factors influencing exacerbation length of treated episodes

The mean (±standard error) total length of exacerbation, delay in initiation of antibiotic treatment, and resolution of all symptoms after the start of antibiotic therapy (61 antibiotic-treated episodes in 17 patients) were 17.5 ± 1.9, 4.4 ± 0.5, and 12.9 ± 1.8 days, respectively.

Of the 61 episodes treated with antibiotics, the exacerbation length was greater the longer the delay in initiation of treatment ([Table 2](#t2-copd-7-789){ref-type="table"}). This relationship was stronger when episodes also treated with steroids were excluded (49 episodes in 15 patients; [Table 2](#t2-copd-7-789){ref-type="table"} and [Figure 3](#f3-copd-7-789){ref-type="fig"}).

The length of any treated episode was related to Anthonisen criteria, with type 1 exacerbations lasting longer than type 2, which in turn were longer than type 3 (*P* = 0.001). However, the average length for all treated episodes correlated negatively with the PD15, with longer episodes relating to lower lung density ([Table 2](#t2-copd-7-789){ref-type="table"}). When analyzed using the linear regression stepwise model, the number of Anthonisen symptoms was the best independent predictor of length of any treated episode. We found no association of length with any of the baseline lung function parameters.

### Factors affecting delay in initiation of antibiotic treatment

The delay in commencing treatment was shorter in patients with lower absolute FEV~1~, FEV~1~/FVC ratio, and PD15 at baseline (r = 0.272, *P* = 0.036, r = 0.461, *P \<* 0.001, and r = 0.786, *P \<* 0.001; [Table 2](#t2-copd-7-789){ref-type="table"}) and with a higher symptom score on day 1 (r = −0.368, *P* = 0.004). When analyzed using stepwise linear regression, baseline lung density emerged as the best independent predictor of delay in treatment (*P* = 0.004), and this association is summarized in [Figure 4](#f4-copd-7-789){ref-type="fig"}.

### Factors affecting treated episode symptom score severity

There was a significant negative correlation between symptom score on day 1 and baseline FEV~1~, FEV~1~/VC%, and lung density (81 episodes; [Table 2](#t2-copd-7-789){ref-type="table"}). No relationship was found with KCO. When analyzed using stepwise linear regression, FEV~1~ emerged as the best independent predictor of poorer symptom score on day 1 (*P* = 0.019).

### Factors affecting resolution of exacerbation after treatment initiation

Resolution of symptoms after the start of antibiotic treatment was not affected by delay in the start of therapy. However, there was a significant negative correlation between resolution and KCO% predicted ([Table 2](#t2-copd-7-789){ref-type="table"} and [Figure 5](#f5-copd-7-789){ref-type="fig"}). No other factor affected resolution time following initiation of treatment.

Discussion
==========

Exacerbations of usual COPD have been well described. The current study allows insight into the factors that influence the management and resolution of exacerbations in a more highly characterized group of patients with AAT deficiency. The data show that exacerbations are more likely to lead to therapeutic intervention in subjects with more severe impairment of FEV~1~ and FEV~1~/FVC at baseline, and in whom more symptoms show deterioration. These two features are interdependent and are consistent with published studies in usual COPD,[@b39-copd-7-789],[@b49-copd-7-789],[@b50-copd-7-789] indicating that the more severe the underlying functional impairment, the more marked the impact of exacerbations.

The overall length of the episode was related to delay in starting antibiotic treatment, although the time from treatment initiation to resolution was unaltered. These data suggest that the overall length of an exacerbation would therefore be reduced by earlier intervention and supports the aims of patient self-management programs in usual COPD.[@b51-copd-7-789],[@b52-copd-7-789]

The AAT deficiency variant is rare, so precludes the study of large numbers of patients, other than superficially or as part of a formal clinical trial. Nevertheless, these unique data enable some new conclusions to be drawn. We have shown that, in addition to spirometry, other physiologic measures (KCO) and radiologic quantification of emphysema (PD15) are also related to exacerbations and their features. The exacerbation frequency was related to KCO% predicted, as was the length of recovery after initiation of treatment. Furthermore, the delay in start of treatment was also dependent on baseline lung density, and multivariate analysis confirmed that this was the best independent predictor of this feature of the episode.

Although previous studies have explored the relationship between airflow obstruction and the frequency, severity, and resolution of exacerbations in usual COPD,[@b49-copd-7-789],[@b50-copd-7-789],[@b53-copd-7-789] the current study suggests that (at least in AAT deficiency-related COPD) lung density by computed tomography, a more direct measure of emphysema, plays an equal if not more important role in determining several aspects of these episodes. Of particular importance is that the data highlight lung densitometry as a measure that has an impact on yet another feature of COPD, ie, exacerbations, in addition to activity,[@b54-copd-7-789] health status,[@b55-copd-7-789] and mortality.[@b56-copd-7-789] Therefore, assessment of the presence and severity of emphysema should become a routine part of the characterization of COPD patients because these data influence many clinical features, possibly including the frequency and time course of exacerbations, as shown here for AAT deficiency. These COPD features (unlike FEV~1~ measurement) are less amenable to therapeutic intervention, and this observation may partly explain why accepted therapies only produce a modest effect on exacerbations and their frequency.[@b20-copd-7-789]--[@b25-copd-7-789] It is clear that further studies in a group of usual COPD subjects are warranted.

Limitations of our study include the fact that the number of subjects studied was small (although large for this genetic subset) and not all episodes had daily data recorded before, during, and after the exacerbation. The analysis was also limited to those episodes treated by an intervention because this permitted a delay in treatment and its effect on the time to resolution to be determined. Nevertheless, the detailed physiologic and radiologic characteristics of the patients enabled their role to be investigated, providing insight into factors other than spirometry that may influence the features of the episodes. Apart from the small number of patients, our study could be influenced by involvement in the trial itself, which may influence patient behavior. In addition, 11 of the patients were receiving active AAT therapy. Although this did not influence the frequency of exacerbations in the full trial,[@b57-copd-7-789] it is possible that it may have had an effect on characteristics. Nevertheless, the new observations of the relationship to emphysema as determined by gas transfer and densitometry remains of interest and worthy of further study.

In summary, these data build on our previous documentation of features that relate to an exacerbation being treated or untreated in AAT deficiency. The components of the treated exacerbation are dependent upon the severity of the underlying disease and the speed of intervention. The presence of emphysema, and especially lung density, have a greater influence than spirometry on some exacerbation features, and these factors should be included in overall patient assessment for prognosis and determining the correct course of management.
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![Diagrammatic representation of exacerbation length and components.](copd-7-789f1){#f1-copd-7-789}

![Correlation between KCO (% predicted) and frequency of 164 treated exacerbations in 21 patients.\
**Notes:** Each point is the average number of treated episodes/year for each patient. The correlation coefficient (r) and significance of the relationship are shown.\
**Abbreviation:** KCO, corrected gas transfer.](copd-7-789f2){#f2-copd-7-789}

![Relationship between delay in starting antibiotic treatment and length of exacerbation.\
**Notes:** Each point represents an individual antibiotic-only treated (no systemic steroid) episode (n = 49 in 15 patients). The correlation coefficient (r) and significance are shown.](copd-7-789f3){#f3-copd-7-789}

![Association between treatment delay and baseline PD15.\
**Notes:** Each point represents the average delay for each of the 15 patients whose antibiotic-treated episodes were studied in detail. The correlation coefficient (r) is shown, together with the significance of the relationship.\
**Abbreviation:** PD15, 15th percentile lung density.](copd-7-789f4){#f4-copd-7-789}

![Relationship between gas transfer and resolution of exacerbation after treatment start.\
**Notes:** Each point represents the average resolution time for each of the 15 patients who experienced and documented antibiotic-treated episodes. The value for the coefficient (r) and the *P*-value are again shown.\
**Abbreviation:** KCO, corrected gas transfer.](copd-7-789f5){#f5-copd-7-789}

###### 

Patient characteristics

  Patient characteristics                  Mean (SE)
  ---------------------------------------- ---------------------------------
  Total number of patients: female, male   N = 23: 6, 17
  Age (years)                              52.5 (2.1)
  Smoking history                          21 ex-smokers, two never smoked
  Pack -- years                            20.7 (3.1)
  FEV~1~ post-BD in L                      1.2 (0.1)
  FEV~1~% predicted                        38.4 (3.1)
  FEV~1~/VC%                               30 (2.7)
  KCO (mmol/min/kpa/L)                     0.9 (0.4)
  KCO (% predicted)                        59.7 (2.9)
  PD15 baseline (g/L)                      44.55 (3.6)

**Abbreviations:** BD, bronchodilator; FEV~1~, forced expiratory volume in one second; KCO, corrected gas transfer; VC, vital capacity; PD15, 15th percentile lung density

###### 

Factors that influence exacerbation features

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factors influencing exacerbation features   Features of the exacerbations                                                                                                                                                                                                                                                                                                                                                                              
  ------------------------------------------- ----------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------
  Spirometry FEV~1~                           ns                                        [a](#tfn3-copd-7-789){ref-type="table-fn"}r = −0.386; *P* = 0.038            ns                                                                                                [c](#tfn5-copd-7-789){ref-type="table-fn"}r = 0.272; *P* = 0.036             [c](#tfn5-copd-7-789){ref-type="table-fn"}**r =** −**0.234;*P*= 0.003**                              ns

  FEV~1~/FVC                                                                            [b](#tfn4-copd-7-789){ref-type="table-fn"}r = −0.460; *P* = 0.013 (N = 21)                                                                                                     [b](#tfn4-copd-7-789){ref-type="table-fn"}r = 0.461; *P* \< 0.001 (N = 17)   [b](#tfn4-copd-7-789){ref-type="table-fn"}**r =** −**0.322;*P*\< 0.001 (N = 81 treated episodes)**   

  KCO% pred                                   ***r*=** −**0.432;*P*= 0.022 (N = 21)**   ns                                                                           ns                                                                                                ns                                                                           **ns**                                                                                               ***r*=** −**0.647;*P*= 0.007 N = 15**

  Delay in treatment initiation in days                                                                                                                              All treated (N = 81 episodes) [d](#tfn6-copd-7-789){ref-type="table-fn"}r = 0.317; *P* = 0.006\   --                                                                           r = −0.368; *P* = 0.004 (N = 81 treated episodes)                                                    **ns**
                                                                                                                                                                     Antibiotic only treated (N = 49 episodes)\                                                                                                                                                                                                                                          
                                                                                                                                                                     [e](#tfn7-copd-7-789){ref-type="table-fn"}r = 0.503; *P* \< 0.001                                                                                                                                                                                                                   

  Anthonisen criteria types                                                             **Chi-square,*P*\< 0.001**                                                   Chi-square, *P* = 0.001 (N = 17)                                                                  --                                                                           Type 1 \> Type 2 \> Type 3, *P* \< 0.001 (N = 21)                                                    --

  Lung densitometry (PD15)                    ns                                        --                                                                           r = −0.361; *P* = 0.003 (N = 81 episodes)                                                         ***r*= 0.786;*P*\< 0.001 (N = 15)**                                          r = −0.170; *P* = 0.035 (N = 81 episodes)                                                            ns

  Cold symptom                                --                                        **Chi-square,*P*\< 0.001**                                                   Chi-square, *P* \< 0.001                                                                          **ns**                                                                       Chi-square, *P* \< 0.001 (N = 21)                                                                    ns
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

FEV~1~% predicted;

FEV~1~/VC ratio;

absolute FEV~1~;

all episodes treated with antibiotics;

episodes also treated with steroids excluded. The features of the exacerbations are outlined as frequency of treated episodes, the likelihood of the episode being treated, length of the episode, delay in commencing treatment, severity of symptoms on day 1 of the episode, and time to resolution following the start of therapy. The factors that relate to these features are shown (see text for further details for each feature). Correlation coefficients (positive or negative) and *P*-values of the correlations are reported. The factor that is the best independent predictor of the feature from multivariate analysis is highlighted in bold font.

**Abbreviations:** FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; KCO, corrected gas transfer; PD15, 15th percentile lung density; N, number of patients; ns, not significant.
